araag2/HINT huggingface dataset:
Clinical trial NCT01212757 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: apremilast 20mg, apremilast 30mg, placebo + 20 mg apremilast, placebo + 30 mg apremilast
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females, aged ≥ 18 years at time of consent.

          -  Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.

          -  Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at time of
             screening.

          -  Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)

          -  May not have axial involvement alone

          -  Concurrent Treatment allowed with methotrexate, leflunomide, or sulfasalazine

          -  Have ≥ 3 swollen AND ≥ 3 tender joints.

          -  Males & Females must use contraception

          -  Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose
             oral corticosteroids allowed.

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  History of allergy to any component of the investigational product.

          -  Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.

          -  Therapeutic failure on > 3 agents for PsA or > 1 biologic tumor necrosis factor (TNF)
             blocker
Clinical trial NCT00603902 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: lorcaserin 10 mg once daily (qd), lorcaserin 10 mg twice a day (bid), matching placebo
SMILES: COC1=CC=CC=C1OCC(O)CO, COC1=CC=CC=C1OCC(O)CO, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Overweight and/or obese men and women with a body mass index (BMI) 30 to 45 kg/m2 with
             or without a comorbid condition (e.g., hypertension, dyslipidemia, CV disease, glucose
             intolerance, sleep apnea), or 27 to 29.9 kg/m2 with at least one comorbid condition.

          -  Ability to complete a 1 year study

        Exclusion Criteria:

          -  Pregnancy

          -  Diabetes mellitus (type I, II or other)

          -  History of symptomatic heart valve disease

          -  Serious or unstable current or past medical conditions
Clinical trial NCT00432237 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: mk0974 50 mg, mk0974 150 mg, mk0974 300 mg, comparator: placebo
SMILES: [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has at least 1 year history of migraine (with or without aura)

          -  Females of childbearing years must use acceptable contraception throughout trial

        Exclusion Criteria:

          -  Patient is pregnant/breast-feeding (or is a female expecting to conceive during the
             study period)

          -  Patient has history or evidence of uncontrolled diabetes, or Human Immunodeficiency
             Virus (HIV) disease. Patient has uncontrolled cardiovascular disease

          -  Patient has major depression, other pain syndromes that might interfere with study
             assessments, psychiatric conditions, dementia, or significant neurological disorders
             (other than migraine)

          -  Patient has a history of gastric or small intestinal surgery or has a disease that
             causes malabsorption

          -  Patient has a history of cancer within the last 5 years
Clinical trial NCT00412373 (phase 3, status: completed)
Conditions: schizoaffective disorder, psychotic disorder
ICD codes: F25.9, F25.0, F25.1, F25.8, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: placebo, paliperidone er, paliperidone er
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of
             schizoaffective disorder

          -  A total Positive and Negative Symptoms of Schizophrenia (PANSS) score of >= 60

          -  A score of >= 16 on Young Mania Rating Scale (YMRS) or a score of >= 16 on the
             Hamilton Depression Rating Scale (HAM-D 21)

        Exclusion Criteria:

          -  A primary active mental illness diagnosis other than schizoaffective disorder

          -  Patients with first episode psychosis

          -  Active substance dependence within previous 6 months

          -  Treatment with clozapine within 6 months of randomization

          -  A history of treatment resistance, defined by failure to respond to 2 adequate trials
             of antipsychotic medication

          -  Pregnancy, breast-feeding, or planning to become pregnant
Clinical trial NCT00423657 (phase 3, status: completed)
Conditions: bacterial infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: ceftaroline, vancomycin plus aztreonam, placebo
SMILES: [H][C@]12SCC(SC3=NC(=CS3)C3=CC=[N+](C)C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC)\C1=NSC(NP(O)(O)=O)=N1)C([O-])=O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires
             significant surgical intervention, or cellulitis or abscess on lower extremity which
             occurs in subjects with diabetes mellitus or well-documented peripheral vascular
             disease.

        Exclusion Criteria:

          -  Prior treatment of current complicated skin and skin structure infection (cSSSI) with
             an antimicrobial.

          -  Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior
             isolation of an organism with in vitro resistance to vancomycin or aztreonam.
Clinical trial NCT00289198 (phase 3, status: completed)
Conditions: rhinitis, allergic, perennial
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1
Drugs: ff, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of perennial allergic rhinitis (PAR).

          -  Must comply with study procedures and be literate.

        Exclusion Criteria:

          -  Significant concomitant medical conditions.

          -  Use of corticosteroids.

          -  Use of allergy and other identified medications during the study.

          -  Current tobacco use or tobacco use within the past year.

          -  Exposure to an investigational study drug within the past 12 months.

          -  Clinically significant abnormal electrocardiograms (ECG) or laboratory abnormality.
Clinical trial NCT00384046 (phase 3, status: completed)
Conditions: hypoactive sexual desire disorder
ICD codes: F52.0
Drugs: testosterone, placebo
SMILES: CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women will be screened for study participation according to the following inclusion
             criteria at Week -4. Eligible women must be a woman one year post menopausal, 40-70
             years old in general good health on transdermal HRT and in a stable monogamous sexual
             relationship with low sexual desire causing distress.

        Exclusion Criteria:

          -  Women will be screened for study participation according to the following exclusion
             criteria at Week -4 or as specified. Eligible women must not have any medical,
             physical, psychological, or pharmacological condition that could confound safety or
             efficacy.
Clinical trial NCT00152022 (phase 3, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: neutral salts of dextroamphetamine sulfate, usp, amphetamine sulphate, usp, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
SMILES: C[C@H](N)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of ADHD

          -  Baseline ADHD-RS-IV score >= 32

          -  Non-pregnant females of childbearing potential must comply with contraceptive
             restrictions.

        Exclusion Criteria:

          -  Significantly underweight or morbidly obese

          -  Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or
             severe Axis I disorders

          -  History of seizure, tic disorder, or a current diagnosis and/or family history of
             Tourette's Disorder

          -  Females who are pregnant or lactating
Clinical trial NCT00376883 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: pamidronate
SMILES: NCCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  New diagnosed multiple myeloma with treatment demanding disease

        Exclusion Criteria:

          -  Life-expectancy less than 3 months, another active malignant disease, treatment with
             bisphosphonates for more than 3 months within the last 6 months, patients with
             creatinine above 400 µmol/l 4 weeks after starting chemotherapy, patients who cannot
             cooperate for monthly infusions, patients who do not give their informed consent
Clinical trial NCT01152996 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vortioxetine
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Has completed either study LuAA21004_315 ( NCT01153009), LuAA21004_316 (NCT01163266),
             or LuAA21004_317 (NCT01179516) immediately prior to enrollment in the extension study
             (ie, the baseline visit is the same visit as the Week 8 [Lu AA21004_317] or Week 10
             [Lu AA21004_315 or Lu AA21004_316] assessment of the preceding protocol).

          -  Suffers from a recurrent major depressive episode) as the primary diagnosis according
             to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
             Revision (DSM-IV-TR) criteria (classification code 296.3x) at entry into the prior
             study.

          -  Twelve-month continuation treatment with Lu AA21004 is indicated for the treatment of
             this participant according to the opinion of the investigator.

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner agree to routinely use adequate contraception throughout the duration of the
             study.

        Exclusion Criteria:

          -  Has Major Depressive Disorder for whom other psychiatric disorders (mania, bipolar
             disorder, schizophrenia, or any psychotic disorder) have been diagnosed during the
             prior study.

          -  In the investigator's clinical judgment, has a significant risk of suicide and/or a
             score of ≥5 points on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression
             Rating Scale (MADRS).

          -  In the opinion of the investigator, is unlikely to comply with the clinical study
             protocol or is unsuitable for any reason.

          -  Has a clinically significant moderate or severe ongoing adverse event related to study
             medication from the prior study.

          -  Has used/uses disallowed concomitant medication.
Clinical trial NCT00731549 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: aripiprazole im depot
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who are able to provide written informed consent and/or consent obtained from
             a legally acceptable representative (as require by IRB/IEC), prior to the initiation
             of any protocol-required procedures.

          -  Male and female subjects 18 to 65 years of age, inclusive, at time of informed
             consent.

          -  Subjects who complete Studies 246/247 or who withdrew from the double-blind
             maintenance phase of either study (Phase 4 of Study 246 or Phase 3 of Study 247), or
             new subjects not participating in Studies 246/247.

          -  # Subjects who, in the investigator's judgment, require chronic treatment with an
             antipsychotic medication.

          -  Subjects able to understand the nature of the study and follow protocol requirements,
             including the prescribed dosage regimens, tablet ingestion, IM depot injection,
             discontinuation of prohibited concomitant medications, who can read and understand the
             written word in order to complete patient-reported outcomes measures, and who can be
             reliably rated on assessment scales.

        Exclusion Criteria:

          -  Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including
             schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
             dementia, amnestic or other cognitive disorders. Also, subjects with borderline,
             paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder.

          -  Subjects with schizophrenia that are considered resistant/refractory to antipsychotic
             treatment by history or response only to clozapine.

          -  Subjects with a significant risk of violent behavior or a significant risk of
             committing suicide based on history or investigator's judgment.

          -  Subjects who currently meet DSM-IV-TR criteria for substance dependence; including
             alcohol and benzodiazepines, but excluding caffeine and nicotine, or two positive drug
             screens for cocaine.

          -  Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment
             with aripiprazole or other quinolinones.

          -  Subjects with a history of hypersensitivity to antipsychotic agents.

          -  Subjects with a history of neuroleptic malignant syndrome or clinically significant
             tardive dyskinesia at screening.
Clinical trial NCT01125566 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: bibw 2992, trastuzumab, vinorelbine, vinorelbine
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion criteria:

          -  Histologically confirmed diagnosis of HER2-overexpression breast cancer

          -  Stage IV metastatic disease

          -  Must have progressed on one prior trastuzumab treatment

          -  no more than one prior trastuzumab based therapy regimen (either adjuvant or
             first-line)

          -  Must have received anthracycline and/or taxane based chemotherapy for adjuvant
             treatment of breast cancer or first-line treatment of metastatic breast cancer

          -  Must have (archived) tumour tissue sample available for central re-assessment of
             HER2-status

          -  At least one measurable lesion according to RECIST 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 .

        Exclusion criteria:

          -  Prior treatment with Epidermal Growth Factor Receptor/Human Epidermal Growth Factor
             Receptor(EGFR/HER2)-targeted small molecules or antibodies other than trastuzumab

          -  Prior treatment with vinorelbine

          -  Known pre-existing interstitial lung disease

          -  Active brain metastases

          -  History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable
             angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to
             randomisation.

          -  Cardiac left ventricular function with resting ejection fraction of less than 50%.

          -  Patients unable to comply with the protocol.

          -  Any contraindications for therapy with vinorelbine or trastuzumab.

          -  Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.

          -  Use of any investigational drug within 4 weeks of randomisation.

          -  Inadequate hepatic, renal and haematologic organ function
Clinical trial NCT00263068 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic restless legs syndrome

        Exclusion Criteria:

          -  Subject has an ongoing serious adverse event from SP792 that is assessed to be related
             to the trial medication by the investigator and/or the sponsor.

          -  Subject is pregnant, nursing, or is a woman of child-bearing potential who is not
             surgically sterile, 2 years postmenopausal, or does not consistently use 2 combined
             effective methods of contraception, including at least 1 barrier method, unless
             sexually abstinent.

          -  Subject has any medical or psychiatric condition that, in the opinion of the
             investigator, can jeopardize or would compromise the subject's ability to participate
             in this trial.
Clinical trial NCT00412529 (phase 3, status: completed)
Conditions: hepatitis b, chronic hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1, B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: entecavir, telbivudine
SMILES: CCOC(=O)C1=CC=C(N)C=C1, CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18-70 years of age with documented compensated hepatitis B "e" antigen
             (HBeAg)-positive chronic hepatitis B

          -  Able to comply with study regimen and provide written informed consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Unwilling to use double barrier method of contraception

          -  Co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV) or human
             immunodeficiency virus (HIV)

          -  Received Hepatitis B therapy in the past

          -  Use of immunomodulatory therapy in past 12 months

          -  History of or symptoms of hepatic decompensation or pancreatitis

          -  Frequent or prolonged use of potentially hepatotoxic or nephrotoxic drugs

          -  Concurrent medication likely to preclude compliance with schedule of evaluations

          -  Use of other investigational drugs within 30 days of enrollment

          -  Abnormal laboratory values during screening

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00114686 (phase 3, status: completed)
Conditions: bipolar i disorder, alcohol dependence
ICD codes: F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76, F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, F10.288
Drugs: quetiapine fumarate, lithium, divalproex
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, [Li+], CCCC(CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meets criteria for Bipolar I Disorder with Alcohol dependence

          -  Outpatient Status

          -  Recent history of heavy drinking

        Exclusion Criteria:

          -  Unstable medical illness

          -  Recent antipsychotic use

          -  Poorly controlled Diabetes Mellitus or Diabetes related illness
Clinical trial NCT01210443 (phase 3, status: terminated)
Conditions: hypertension, pulmonary
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: sitaxentan
SMILES: CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl
Reason stopped: 
    safety issue: the trial was prematurely terminated on dec 9, 2010, due to safety concerns,
    specifically new emerging evidence of hepatic injury.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subject who completed the B1321052 study as planned.

        Exclusion Criteria:

          -  Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure
             >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening.

          -  Has hypotension defined as systolic arterial pressure <90 mm Hg after sitting for 5
             minutes at Screening.
Clinical trial NCT00264615 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lamotrigine extended-release
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Confident diagnosis of epilepsy.

          -  Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).

        Exclusion Criteria:

          -  Females of childbearing potential cannot be on hormonal contraceptives or hormone
             replacement therapy.
Clinical trial NCT00645671 (phase 3, status: completed)
Conditions: ocular inflammation
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: 0.5% loteprednol etabonate ophthalmic ointment, vehicle of loteprednol etabonate ophthalmic ointment
SMILES: [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects who are candidate for routine, uncomplicated cataract surgery

          2. Subjects who, in the Investigator's opinion, have potential postoperative pinholed
             Snellen visual acuity (VA) of at least 20/200 in the study eye.

        Exclusion Criteria:

          1. Subjects who will require concurrent ocular therapy with NSAIDs, mast cell
             stabilizers, antihistamines, decongestants, or immunosuppressants (e.g., Restasis), or
             with ocular or systemic corticosteroids

          2. Subjects who have known hypersensitivity or contraindication to the study drug(s) or
             their components

          3. Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye

          4. Subjects who have had ocular surgery (including laser surgery) in the study eye within
             3 months or in the fellow eye within 2 weeks prior to the Screening Visit